AVADEL PHARMACEUTICALS PLC's ticker is AVDL and the CUSIP is 05337M104. A total of 82 filers reported holding AVADEL PHARMACEUTICALS PLC in Q3 2020. The put-call ratio across all filers is 0.74 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2024 | $956,059 | -38.4% | 56,605 | -48.5% | 0.00% | – |
| Q4 2023 | $1,551,858 | +595.0% | 109,905 | +406.9% | 0.00% | – |
| Q3 2023 | $223,304 | -94.7% | 21,680 | -91.6% | 0.00% | -100.0% |
| Q2 2023 | $4,252,664 | +1692.6% | 258,050 | +896.4% | 0.00% | – |
| Q1 2023 | $237,235 | -55.8% | 25,899 | -65.4% | 0.00% | – |
| Q4 2022 | $536,277 | +562.1% | 74,899 | +125.5% | 0.00% | – |
| Q2 2022 | $81,000 | -72.3% | 33,220 | -22.4% | 0.00% | – |
| Q1 2022 | $292,000 | -78.3% | 42,804 | -74.3% | 0.00% | – |
| Q4 2021 | $1,348,000 | +164.3% | 166,869 | +220.9% | 0.00% | – |
| Q3 2021 | $510,000 | +335.9% | 52,000 | +198.9% | 0.00% | – |
| Q2 2021 | $117,000 | -89.3% | 17,397 | -85.6% | 0.00% | – |
| Q1 2021 | $1,094,000 | +835.0% | 121,005 | +589.7% | 0.00% | – |
| Q4 2020 | $117,000 | +23.2% | 17,545 | +50.0% | 0.00% | – |
| Q2 2020 | $95,000 | +66.7% | 11,700 | -15.3% | 0.00% | – |
| Q3 2019 | $57,000 | – | 13,819 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Knoll Capital Management, LLC | 600,000 | $8,436,000 | 5.68% |
| Vivo Capital, LLC | 3,972,099 | $55,847,712 | 5.16% |
| Tri Locum Partners LP | 1,189,518 | $16,724,623 | 4.23% |
| Knott David M Jr | 333,000 | $4,682 | 1.87% |
| MPM BioImpact LLC | 783,242 | $11,012,383 | 1.71% |
| SCHULHOFF & CO INC | 137,000 | $1,926,220 | 0.87% |
| 1620 INVESTMENT ADVISORS, INC. | 1,000 | $14,060 | 0.01% |
| Ameritas Investment Partners, Inc. | 9,055 | $127,313 | 0.00% |
| HUNTINGTON NATIONAL BANK | 1 | $16 | 0.00% |
| CWM, LLC | 99 | $1 | 0.00% |